The latent TB testing market presents opportunities through government support, tech advances in multiplex and molecular diagnostics, POC testing, telemedicine, and personalized medicine. These ...

Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples // Panel significantly accelerates TB outbreak tracking and ...

Breast tuberculosis, a rare form of extrapulmonary tuberculosis, represents a diagnostic challenge due to its nonspecific clinical and imaging features that can mimic both benign and malignant breast ...

Environmental Controls & Personal Protection to Reduce the Risk of Infection In addition to administrative controls, environment controls and personal protection [32] are also essential in reducing ...

The American Thoracic Society (ATS), the U.S. Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of American (IDSA) announce the release of the first completely ...

KARACHI, March 21: Healthcare providers need to be urgently educated about proper tuberculosis management particularly regarding mild to severe side effects of anti-TB drugs. This was discussed in a ...

An ICMR study shows that six-month all-oral treatment regimens for drug-resistant tuberculosis are more economical and effective, outperforming longer plans in India. This finding suggests a ...

One in five multi-drug resistant (MDR) tuberculosis (TB) cases in children under the age of 15 could be averted every year by household contact management, according to a new modeling study published ...

In a recent study published in the journal Clinical Infectious Diseases, researchers reported on the treatment of rifampin-resistant tuberculosis in the United States (U.S.) using the Food and Drug ...

Shorter, six month and alloral treatment regimens for multidrugresistant and rifampicinresistant tuberculosis (MDR/RRTB) are ...

Extensive drug resistance in TB is not a new phenomenon. It is created when patients with multidrug-resistant TB (MDR-TB) are treated with second-line anti-TB drugs but fail to be cured. The first ...